Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Association between Molecular Profile and Outcome after Intensive Chemotherapy in Patients > 60 Years with Adverse Cytogenetic Risk and/or Secondary Acute Myeloid Leukemia - a Filo Study

Corentin Orvain, Anne Bouvier, Audrey Bidet, Pierre-Yves Dumas, Sarah Bertoli, Odile Blanchet, Sylvain Thepot, Aline Schmidt, Arnaud Pigneux, Eric Delabesse, Christian Recher, Hunault-Berger Mathilde

Blood (2023) 142 (Supplement 1): 2851.

https://doi.org/10.1182/blood-2023-184815

Published: 2023

Journal Articles

GATA2 Expression Level in Chronic Myeloid Leukemia (CML) Patients Correlates with Their Prognostic Scores and Is Associated with Disease Stage at Diagnosis

Philippe Guardiola, MD, Corentin Orvain, Nick C.P. Cross, PhD, Martine Gardembas, MD, Marc Spentchian, MD, Estelle Pedrono, PhD, Diane Lambert, PhD, Anne Coutolleau, Anne Bouvier, MD, Odile Blanchet, MDPhD, Nicole Piard, MD, Norbert Ifrah, MD PhD, Frank Giles, MD MB, FRCPI, FRCPath, Andreas Hochhaus, MD, Jerald P. Radich, MD, Philippe Rousselot, MD PhD

Blood (2015) 126 (23): 2768.

https://doi.org/10.1182/blood.V126.23.2768.2768

Published: 2015

Journal Articles

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

Blood (2013) 121 (12): 2213–2223.

https://doi.org/10.1182/blood-2012-10-462879

Published: 2013

Includes: Supplemental data

Journal Articles

Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study

Blood (2012) 119 (12): 2943–2948.

https://doi.org/10.1182/blood-2011-05-352989

Published: 2012

Journal Articles

Single-Agent Dasatinib Does Not Prevent Hematological Relapse in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) in First Complete Remission, but Persistent or Re-Appearing Molecular Minimal Residual Disease–Results of the DASA-CBF Trial From the French AML Intergroup

Blood (2011) 118 (21): 2608.

https://doi.org/10.1182/blood.V118.21.2608.2608

Published: 2011

Journal Articles

IDH1/2, TET2 and DNMT3A Mutations Are Not Mutually Exclusive in Secondary Acute Myeloid Leukemias,

Olivier Kosmider, Olivier LaRochelle, Marie-Magdelaine Coude, Veronique Mansat-De Mas, Eric Delabesse, Pascale Cornillet-Lefebvre, Odile Blanchet, Christian Recher, Alain Delmer, MD, Sophie Raynaud, Catherine Lacombe, Olivier Bernard, Norbert Ifrah, Francois Dreyfus, Michaela Fontenay

Blood (2011) 118 (21): 3556.

https://doi.org/10.1182/blood.V118.21.3556.3556

Published: 2011

Journal Articles

Gene Mutations and Minimal Residual Disease (MRD) As Predictors of Remission Duration in Adults with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Treated with High-Dose Cytarabine (HDAC) - First Results of the Prospective French Intergroup CBF-2006 Trial

Blood (2011) 118 (21): 410.

https://doi.org/10.1182/blood.V118.21.410.410

Published: 2011

Journal Articles

Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study

Blood (2011) 118 (21): 79.

https://doi.org/10.1182/blood.V118.21.79.79

Published: 2011

Journal Articles

Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks

Stefan Deneberg, Philippe Guardiola, Andreas Lennartsson, Ying Qu, Verena Gaidzik, Odile Blanchet, Mohsen Karimi, Sofia Bengtzén, Hareth Nahi, Bertil Uggla, Ulf Tidefelt, Martin Höglund, Christer Paul, Karl Ekwall, Konstanze Döhner, Sören Lehmann

Blood (2011) 118 (20): 5573–5582.

https://doi.org/10.1182/blood-2011-01-332353

Published: 2011

Includes: Supplemental data

Journal Articles

Clinical Phenotype and Response to Imatinib of Chronic Myelogenous Leukemia Patients Harbouring Atypical BCR-ABL Transcripts. A Retrospective Analysis From the French Group of CML (Fi-LMC) and the French Group of Molecular Biologists for Hematological Malignancies (GBMHM).

Benedicte Deau, MD, Mathias Montveneur, MStud, Valérie Coiteux, MD, Aline Renneville, MD, Francoise Rigal-Huguet, MD, Eric Delabesse, MD, PhD, Michel Tulliez, MD, Dominique Bories, MD, PhD, Aude Charbonnier, MD, PhD, Marie-Joelle Mozziconacci, MD, PhD, Thibault Legay, MD, Eric Lippert, PhD, Francois-Xavier Mahon, MD, PhD, Delphine Rea, MD, PhD, Jean-Michel Cayuela, PhD, Shanti Amé, MD, Marie-Pierre Gaub, MD, Martine Gardembas, MD, Odile Blanchet, MD, Bruno Audhuy, MD, Agnès Buzyn, MD, PhD, Elisabeth Mac Intyre, MD, PhD, Anna-Lisa Andreoli, MD, Oumedaly Reman, Nathalie Contentin, MD, Christian Bastard, MD, Jean-Christophe Ianotto, MD, Valérie Ugo, MD, PhD, Jean-Jacques Kiladjian, MD, PhD, Said Brahimi, MD, Viviane Dubruille, Jean-Francois Brantus, MD, Mohamad Sobh, Pharm., M., Stephane Morisset, Stat., Claude Preudhomme, MD, PhD, Sandrine Hayette, PhD, Franck E Nicolini, MD, PhD

Blood (2010) 116 (21): 3378.

https://doi.org/10.1182/blood.V116.21.3378.3378

Published: 2010

Journal Articles

Are Microarray-Derived Gene Expression Signatures Useful as a Routine Assay for Prognostic Evaluation of Acute Myeloid Leukemia Samples with Low Leukemic Blast Content ?.

Philippe Guardiola, MD, Diane Lambert, PhD, Pascale Cornillet-Lefebvre, MD, PhD, Anne Coutolleau, Laurence Baranger, MD, Franck Genevieve, MD, PhD, Isabelle Luquet, MD, PhD, Annaelle Beucher, Marc Zandecki, PhD, Norbert Ifrah, MD, Odile Blanchet, MD, PhD

Blood (2010) 116 (21): 1658.

https://doi.org/10.1182/blood.V116.21.1658.1658

Published: 2010

Journal Articles

TET2 Mutations in Secondary Acute Myeloid Leukemias: A French Retrospective Study

Olivier Kosmider, Véronique De Mas, Eric Delabesse, Pascale Cornillet-lefevre, Odile Blanchet, Christian Récher, Sophie Raynaud, Catherine Lacombe, Olivier Bernard, Norbert Ifrah, Francois Dreyfus, Michaëla Fontenay on behalf of the GOELAMS

Blood (2010) 116 (21): 176.

https://doi.org/10.1182/blood.V116.21.176.176

Published: 2010

Journal Articles

Influence of NPM1 and FLT3-ITD Status On Outcome in Relapsed/Refractory AML Patients with Normal Karyotype and Receiving Salvage Therapy Including Gemtuzumab Ozogamicin (GO).

Patrice Chevallier, MD, Thomas Prebet, MD, Arnaud Pigneux, MD, PhD, Mathilde Hunault, MD, Jacques Delaunay, Frederic Perry, Laurence Lode, Steven Richebourg, Odile Blanchet, Norbert Vey, Norbert Ifrah, MD, Noel-Jean Milpied, MD, Didier Blaise, MD, Jean-Luc Harousseau, Mohamad Mohty, MD, PhD

Blood (2009) 114 (22): 3110.

https://doi.org/10.1182/blood.V114.22.3110.3110

Published: 2009

Journal Articles

FOXC1, a New Prognostic Marker in Adult Acute Myeloid Leukemia (AML).

Odile Blanchet, MD, PhD, Frederique Galopin, MD, Derek Stirewalt, MD, Mathilde Hunault-Berger, MD, PhD, Annaelle Beucher, Era Pogosova-Agadjanyan, Lejla Ibricevic, MD, Laurence Baranger, MD, Franck Genevieve, MD, Marc Zandecki, MD, PhD, Norbert Ifrah, MD, Jerald P. Radich, MD, Philippe Guardiola, MD

Blood (2007) 110 (11): 2387.

https://doi.org/10.1182/blood.V110.11.2387.2387

Published: 2007

Journal Articles

Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients

Jerome Tamburini, Caroline Elie, Valérie Bardet, Nicolas Chapuis, Sophie Park, Philippe Broët, Pascale Cornillet-Lefebvre, Bruno Lioure, Valérie Ugo, Odile Blanchet, Norbert Ifrah, Francis Witz, François Dreyfus, Patrick Mayeux, Catherine Lacombe, Didier Bouscary

Blood (2007) 110 (3): 1025–1028.

https://doi.org/10.1182/blood-2006-12-061283

Published: 2007

Journal Articles

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years

Philippe Rousselot, Francoise Huguet, Delphine Rea, Laurence Legros, Jean Michel Cayuela, Odile Maarek, Odile Blanchet, Gerald Marit, Eliane Gluckman, Josy Reiffers, Martine Gardembas, François-Xavier Mahon, The Intergroupe Français des Leucémies Myéloïdes Chronique (FIφLMC)

Blood (2006) 109 (1): 58–60.

https://doi.org/10.1182/blood-2006-03-011239

Published: 2006

Journal Articles

Atypical BCR-ABL Transcripts Chronic Myelogenous Leukemias Show Particular Features, and Their Classical Worse Prognosis Seems Abrogated by Imatinib Mesylate. A Retrospective Analysis of 22 Patients, on the Behalf of the French Intergroup of CML (Fi(ϕ)-LMC Group).

Franck E. Nicolini, MD, PhD, Nathalie Grardel, MD, Sandrine Hayette, PhD, Jean-Michel Cayuela, MD, Agnès Buzyn, MD, PhD, Eric Delabesse, MD, Christian Bastard, MD, Odile Blanchet, MD, Nathalie Sorel, PhD, Marie-Josée Mozziconacci, MD, Ali Turhan, MD, PhD, Virginie Eclache, MD, François-Xavier Mahon, MD, PhD, Nicole Dastugue, MD, Eric Legac, MD, Marie-Pierre Gaub, MD, Sélim Corm, MD, Claude Preudhomme, MD, PhD

Blood (2005) 106 (11): 3285.

https://doi.org/10.1182/blood.V106.11.3285.3285

Published: 2005

Journal Articles

Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial

Blood (2004) 104 (10): 3028–3037.

https://doi.org/10.1182/blood-2003-10-3560

Published: 2004

Journal Articles

Several Cytogenetic Subclones May Be Identified Within Plasma Cells From Patients With Monoclonal Gammopathy of Undetermined Significance, Both at Diagnosis and During the Indolent Course of This Condition

Marc Zandecki, Jean-Luc Laı̈, Franck Geneviève, Franck Bernardi, Hélène Volle-Rémy, Odile Blanchet, Michel François, Alain Cosson, Francis Bauters, Thierry Facon

Blood (1997) 90 (9): 3682–3690.

https://doi.org/10.1182/blood.V90.9.3682

Published: 1997

NARROW

Association between Molecular Profile and Outcome after Intensive Chemotherapy in Patients > 60 Years with Adverse Cytogenetic Risk and/or Secondary Acute Myeloid Leukemia - a Filo Study

GATA2 Expression Level in Chronic Myeloid Leukemia (CML) Patients Correlates with Their Prognostic Scores and Is Associated with Disease Stage at Diagnosis

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study

Single-Agent Dasatinib Does Not Prevent Hematological Relapse in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) in First Complete Remission, but Persistent or Re-Appearing Molecular Minimal Residual Disease–Results of the DASA-CBF Trial From the French AML Intergroup

IDH1/2, TET2 and DNMT3A Mutations Are Not Mutually Exclusive in Secondary Acute Myeloid Leukemias,

Gene Mutations and Minimal Residual Disease (MRD) As Predictors of Remission Duration in Adults with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Treated with High-Dose Cytarabine (HDAC) - First Results of the Prospective French Intergroup CBF-2006 Trial

Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study

Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks

Clinical Phenotype and Response to Imatinib of Chronic Myelogenous Leukemia Patients Harbouring Atypical BCR-ABL Transcripts. A Retrospective Analysis From the French Group of CML (Fi-LMC) and the French Group of Molecular Biologists for Hematological Malignancies (GBMHM).

Are Microarray-Derived Gene Expression Signatures Useful as a Routine Assay for Prognostic Evaluation of Acute Myeloid Leukemia Samples with Low Leukemic Blast Content ?.

TET2 Mutations in Secondary Acute Myeloid Leukemias: A French Retrospective Study

Influence of NPM1 and FLT3-ITD Status On Outcome in Relapsed/Refractory AML Patients with Normal Karyotype and Receiving Salvage Therapy Including Gemtuzumab Ozogamicin (GO).

FOXC1, a New Prognostic Marker in Adult Acute Myeloid Leukemia (AML).

Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years

Atypical BCR-ABL Transcripts Chronic Myelogenous Leukemias Show Particular Features, and Their Classical Worse Prognosis Seems Abrogated by Imatinib Mesylate. A Retrospective Analysis of 22 Patients, on the Behalf of the French Intergroup of CML (Fi(ϕ)-LMC Group).

Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial

Several Cytogenetic Subclones May Be Identified Within Plasma Cells From Patients With Monoclonal Gammopathy of Undetermined Significance, Both at Diagnosis and During the Indolent Course of This Condition

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only